Tenofovir alafenamide

Drug Profile

Tenofovir alafenamide

Alternative Names: GS-7340; GS-7340-02; TAF; Vemlidy

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hepatitis B
  • Phase III HIV-1 infections

Most Recent Events

  • 11 Jan 2017 Registered for Hepatitis B (Treatment-naive, Treatment-experienced, In adolescents, In adults) in Liechtenstein, Iceland, Norway, European Union (PO)
  • 19 Dec 2016 Registered for Hepatitis B (Treatment-naive, Treatment-experienced) in Japan (PO)
  • 01 Dec 2016 Gilead Sciences initiates enrolment in a phase III trial for Hepatitis B (Treatment-experienced) in USA (PO, Tablet) (NCT02979613)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top